Correlations between 3D mitral valve parameters and left ventricular remodeling at 6 months after ST elevation myocardial infarction: pilot study

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
A.I Scarlatescu ◽  
S Onciul ◽  
A Pascal ◽  
D Zamfir ◽  
I Petre ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Mitral Valve ◽  
Mitral Annulus ◽  
3D Echocardiography ◽  
Funding Source ◽  
Posterior Leaflet ◽  
Anterior Leaflet ◽  
Lv Remodeling ◽  
St Elevation

Abstract Background Mitral valve regurgitation and LV remodeling are associated with worse prognosis in acute ST elevation myocardial infarction (STEMI) patients. 3D echocardiography provides a more accurate assessment of mitral ring and leaflet remodeling thus offering a better understanding of mitral valve (MV) and LV geometrical changes in time. Purpose We aimed to assess the echocardiographic evidence of the mitral valve geometrical changes after STEMI. Methods In this prospective study we included 30 consecutive patients aged between 35 and 68 years old, with STEMI treated by primary PCI. All underwent conventional transthoracic echocardiography. In addition to conventional parameters we measured LV global longitudinal strain (GLS) and mitral valve parameters using 3D echocardiography (4D MV Assessment 2.2 software). All measuremets were performed at baseline and at 6 month follow up. LV remodeling was defined as an increase of over 15% of the LV end diastolic volume (LVEDV) at 6 months after the STEMI. Results We found significant differences in time between LVEF (39.22% vs 43.63%, p=0.00), VTDVS (116ml vs 120ml, p=0.00), LV GLS (−13.41 vs −15.52, p=0.10). LV remodeling at 6 months after STEMI has been observed in 17% of the patients. Regarding the type of the infarction, in anterior STEMI, anterior leaflet surface increased in time (from 6.44cmp vs 7.42cmp, p=0.05), while there was no significant change in posterior leaflet area. In inferior STEMI, the area of posterior mitral leaflet decreased (4.8 cmp vs 4.5 cmp, p=0.52) as well as the leaflet length (1.42 cm vs 1.19 cm p=0.003), but the anterior leaflet remained the same. At 6 months we observed significant differences between the 2 groups (with and without LV remodeling) in the following mitral valve 3D parameters: mitral annulus area (2.6 cmp vs 1.67 cmp, p=0.02), mitral circumference (2.57 cm vs 1.74 cm, p=0.021), bicomisural diameter (2.66 cm vs 2.16 cm, p=0.018), tenting area (p=0.009), anterior leaflet length (2,66 cm vs 2,015 cm p=0.018) and anterior leaflet area (3,69 cmp vs 2.49 cmp, p=0.002). Baseline LV GLS significantly correlated with the following mitral valve 3D parameters at 6 months: anterior leaflet area, posterior leaflet area, anterior leaflet length, tenting height, tenting area, mitral ring 3D area, anteroposterior and bicommissural diameters and mitral circumference (correlation coefficient >0.5). Using linear regression we proved that LV GLS can predict the shortening of the posterior MV (cut off −12.6, AUC 0.844, p=0.011) after 6 months follow up. These findings were independent of the presence and severity of mitral regurgitation. Conclusion Using 3D echocardiography, significant changes in mitral valve geometry were detected at 6 months follow up in STEMI patients. LV remodeling is associated with increased mitral annulus dimensions. Funding Acknowledgement Type of funding source: Other. Main funding source(s): This work was supported by CREDO Project - ID: 49182, financed through the SOP IEC -A2-0.2.2.1-2013-1 cofinanced by the ERDF.

scholarly journals 1182 Clinical evidence of the mitral valve leaflet remodeling after st-elevation acute myocardial infarction: longitudinal observation using real-time 3D echocardiography

2020 ◽  
Vol 21 (Supplement_1) ◽  
Author(s):  
S Nishino ◽  
N Watanabe ◽  
T Kimura ◽  
K Ashikaga ◽  
N Kuriyama ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Mitral Valve ◽  
Clinical Evidence ◽  
Posterior Leaflet ◽  
Anterior Leaflet ◽  
Mitral Valve Leaflet ◽  
St Elevation ◽  
3D Transthoracic Echocardiography

Abstract Background Mitral valve (MV) leaflet remodeling after acute myocardial infarction (AMI) has been proposed as biological and physiological reaction under the ischemic environment mainly by animal experiments. Clinical evidence of leaflet growth after AMI is lacking. Purpose We aimed to assess the clinical evidence of the mitral valve leaflet remodeling after acute myocardial infarction by serial 2D/3D transthoracic echocardiography. Methods Sixty-six patients with first-onset ST-elevation MI (33 anterior and 33 inferior) were serially examined by 2D/3D-transthoracic echocardiography. MV complex geometry including leaflet surface area and leaflet thickness was quantitatively analyzed in acute phase and 6-month follow-up. Results 3D-leaflet surface area was significantly increased in 6-month follow-up (anterior MI; 5.58 [4.93-6.00] versus 5.98 [5.68-6.40] cm²/m²; P < 0.001, inferior MI; 5.48 [4.69-6.07] versus 5.79 [4.74-6.37] cm²/m²; P < 0.001). In anterior MI, both anterior and posterior leaflet lengths significantly increased (anterior leaflet; 12.78 [11.55-13.55] versus 13.63 [12.52-14.15] mm/m²; P = 0.001, posterior leaflet; 9.61 [8.73-10.77] versus 9.84 [8.94-10.96] mm/m²; P = 0.037). In inferior MI, posterior leaflet length significantly increased (9.18 [8.50-10.38] versus 10.00 [8.56-10.85] mm/m²; P = 0.029), while there was no significant change in anterior leaflet length (12.54 [11.61-13.56] versus 12.56 [12.08-14.06] mm/m²; P = 0.214). Leaflet thickness was found to become greater in both groups in 6-month follow-up (anterior MI; 1.08 [0.92-1.21] versus 1.32 [1.25-1.45] mm; P < 0.001, inferior MI; 1.14 [0.98-1.25] versus 1.32 [1.21-1.49] mm; P < 0.001) (Figure). Conclusions In six months from the onset of AMI, MV enlarged in area and increased in thickness. Anterior leaflet mainly enlarged in anterior MI, while posterior leaflet enlarged in inferior MI. This is the first clinical evidence of the MV remodeling after AMI, and long-year follow-up should contribute to assess the course of valve growth with relation to ischemic mitral regurgitation. Abstract 1182 Figure. 3D analysis of the mitral valve

scholarly journals Mitral valve opening in the ovine heart

1998 ◽  
Vol 274 (2) ◽  
pp. H552-H563 ◽  
Author(s):  
Matts O. Karlsson ◽  
Julie R. Glasson ◽  
Ann F. Bolger ◽  
George T. Daughters ◽  
Masashi Komeda ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Three Dimensional ◽  
Mitral Annulus ◽  
Posterior Leaflet ◽  
Anterior Leaflet ◽  
Rapid Fall ◽  
Valve Opening ◽  
Radiopaque Markers ◽  
Edge Separation ◽  
Central Cusp

To study the three-dimensional size, shape, and motion of the mitral leaflets and annulus, we surgically attached radiopaque markers to sites on the mitral annulus and leaflets in seven sheep. After 8 days of recovery, the animals were sedated, and three-dimensional marker positions were measured by computer analysis of biplane videofluorograms (60/s). We found that the oval mitral annulus became most elliptical in middiastole. Both leaflets began to descend into the left ventricle (LV) during the rapid fall of LV pressure (LVP), before leaflet edge separation. The anterior leaflet exhibited a compound curvature in systole and maintained this shape during opening. The central cusp of the posterior leaflet was curved slightly concave to the LV during opening. Markers at the border of the “rough zone” were separated by 10 mm during systole. We conclude that coaptation occurs very near the leaflet edges, that the annulus and leaflets move toward their open positions during the rapid fall of LVP, and that leaflet edge separation, the last event in the opening sequence, occurs near the time of minimum LVP.

scholarly journals Rituximab in patients with acute ST-elevation myocardial infarction (RITA-MI)

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
T.X Zhao ◽  
M Aetesam-Ur-Rahman ◽  
A Sage ◽  
Y Lu ◽  
S Victor ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
B Cells ◽  
Infarct Size ◽  
B Cell ◽  
Cardiac Biomarkers ◽  
Lymphoid Tissues ◽  
Funding Source ◽  
Inflammatory Monocytes ◽  
St Elevation

Abstract Background In pre-clinical models of acute myocardial infarction (MI), mature B cells selectively mobilise inflammatory monocytes into the heart, leading to increased infarct size and deterioration of myocardial function. Anti-CD20 antibody-mediated depletion of B cells limited infarct size and improved cardiac function. Rituximab is a monoclonal antibody targeted against human B cells and has been used in the treatment of autoimmune diseases and cancers. However, its use in cardiovascular disease is untested and is currently contraindicated. Purpose We assessed the safety, feasibility and pharmacodynamic effect of rituximab given acutely to patients with ST-elevation MI (STEMI). Method RITA-MI was a prospective, open-label, dose-escalation, single-arm, phase 1/2a clinical trial, which tested rituximab administered as a single intravenous dose in patients with STEMI within 48 hours of symptom onset. Four escalating doses (200, 500, 700 and 1000mg) were used with 6 patients in each group. Follow-up was performed during initial inpatient stay; on days 6 and 14; and at 3 and 6 months. The primary endpoint was safety, whilst secondary endpoints were changes in B cells and their subsets, immune cell subsets, and cardiac and inflammatory biomarkers. [NCT:03072199] Results Overall, rituximab was well tolerated across all doses with the most common adverse event being gastrointestinal disturbance. This was due to the concomitant oral secondary prevention medication started after a STEMI. Five severe adverse events were reported, none of which were assessed as being related. Rituximab caused a mean 96.3% (95% CI 93.8–98.8%) depletion of B cell within 30 mins of the infusion starting across all dose groups. At 6 hours a rebound in B cells was seen in the 200, 500 and 700mg doses, likely related to the emigration of B cells from secondary lymphoid tissues. Maximal B cell depletion was seen at day 6, which was lower than baseline for all doses (p<0.001) (figure 1). B cell repopulation at 6months was dose-dependent. In addition, there was modulation of returning B cell subsets characterised by increased transitional B cells (figure 1C). Immunoglobulin (IgG, IgM and IgA) levels were not affected during follow-up. Rituximab also caused an acute and transient decrease in lymphocytes (both CD4+ and CD8+ T cells) and monocytes, whilst transiently increasing neutrophils at the 6-hour timepoint. Cardiac biomarkers showed a decrease in CRP and BNP. Clinical echocardiogram showed an increase in ejection fraction at follow up (mean increase in EF of 7.8% (95% CI 3.11–12.6)). Conclusion Rituximab appears safe and feasible when given in acute STEMIs. We have shown for the first time that depletion of B cells within 30mins of starting rituximab which demonstrates the biological plausibility of our treatment paradigm. Additional new insight into the mechanism of action of rituximab was found. This has led directly to the setting up of a phase 2b trial. Funding Acknowledgement Type of funding source: Public grant(s) – EU funding. Main funding source(s): European Union Research Council

scholarly journals Prediction of left ventricular remodeling following ST elevation myocardial infarction: role of myocardial deformation parameters

2021 ◽  
Vol 22 (Supplement_1) ◽  
Author(s):  
AI Scarlatescu ◽  
S Onciul ◽  
A Pascal ◽  
I Petre ◽  
D Zamfir ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Regression Analysis ◽  
Left Ventricular ◽  
St Elevation Myocardial Infarction ◽  
Mechanical Dispersion ◽  
Significant Difference ◽  
Lv Remodeling ◽  
Adverse Remodeling ◽  
St Elevation

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – EU funding. Main funding source(s): This work was supported by CREDO Project - ID: 49182, financed through the SOP IEC -A2-0.2.2.1-2013-1 cofinanced by the ERDF - I agree that this information can be anonymised and then used for statistical purposes only Background Left ventricular (LV) remodeling after ST elevation myocardial infarction (STEMI) plays an important role in predicting the outcome of this patient group. It is also useful in assessing the benefit of revascularization. Its identification is also of clinical importance in order to set up preventive strategies for patients with adverse remodeling Purpose To find an echocardiographic predictor of LV adverse remodeling following STEMI. Materials and methods In this prospective study we included 52 consecutive patients, aged between 35-70,  with STEMI treated by primary PCI. We performed conventional 2D transthoracic echocardiography for patients. In addition to conventional parameters we also measured LV global longitudinal strain (GLS) and LV mechanical dispersion using 2D speckle tracking imaging. For morphological and functional analysis of LV we used 3D echocardiography (volumes, LVEF). LV remodeling (LVR) was defined as an increase of over 15% of the LV end diastolic volume (LVEDV) at 6 months follow up. Results We found significant differences in time (baseline and 6 month follow up) between LVEF (43,08 vs 47,91, p = 0.034), LVEDV (105,95 vs 113,21, p = 0.000), LV GLS (-12.61 vs - 14,58, p = 0.01), and mechanical dispersion (61,68 vs 56,11, p = 0.00) in all patients. LV remodeling at 6 months (15% increase in LVEDV) was observed in 30 % of the included patients. At 6 months after STEMI we observed a significant difference between the two groups (remodeling vs no remodeling) regarding 3D LVEF (42.28 %vs 50.30%,p = 0.009), LVEDV (131 ml vs 109 ml, p = 0.05), GLS (-11.15 vs -16.02, p = 0.00) and LV mechanical dispersion (69.02 vs 50.54, p = 0.00). Patients with LV remodeling at 6 months after STEMI had lower LVEF, worse LV GLS and higher LV mechanical dispersion at baseline. Using ROC curve analysis we identified two cut off values, one of -11.55 for baseline LV GLS (Sb 78%, Sp 81%, AUC 0.852, CI 95%, p = 0.00) and another one of 63.7 for LV baseline mechanical dispersion (Sb 71,4%, Sp 66 %, AUC 0.762, p 0.005) to discriminate between patients with or without LV adverse remodeling at 6 months. Using linear regression analysis, we demonstrated that GLS (p = 0.00) and LV mechanical dispersion (p = 0.016) are able to predict LV remodeling in time. We also found a negative correlation between peak CK-MB levels at baseline LVEF at 6 months. Regression analysis showed that CK-MB levels at baseline could predict LVEF at 6 months (p = 0.008) Conclusion Baseline LV mechanical dispersion and LV GLS can predict LV adverse remodeling at 6 months after STEMI. These parameters could be used at baseline in order to predict worse outcome in STEMI patients. Further larger scale studies are needed to validate these findings.

Premolded Bovine Pericardial Chords for Replacement of Ruptured or Elongated Chordae Tendineae

2010 ◽  
Vol 13 (1) ◽  
pp. 17
Author(s):  
Francisco Gregori ◽  
Jo�o Carlos Leal ◽  
Domingo Marcolino Braile
Keyword(s):  
Pulmonary Embolism ◽  
Mitral Valve ◽  
Early Postoperative Period ◽  
Time Range ◽  
Mitral Insufficiency ◽  
Posterior Leaflet ◽  
Anterior Leaflet ◽  
Chordae Tendineae ◽  
Leaflet Coaptation

Background: The aim of this study was to assess by Doppler echocardiography (ECO) the functioning of the mitral valve apparatus in patients who have undergone implantation of standardized bovine pericardium chordae (SBPC) for replacement of ruptured or elongated chordae tendineae with significant thinning.Methods: SBPC were implanted in 31 patients who had mitral insufficiency due to rupture of chordae tendinae or elongated chordae with significant thinning. Patient ages ranged from 19 to 85 years (mean of 58 years). The most frequent cause of mitral insufficiency was fibroelastic degeneration in 25 patients (80.6%). The SBPC were fashioned as a set, joined at their extremities by 2 polyester-reinforced rods forming a monobloc. The SBPC were 2-mm wide and were positioned parallel to one another at a distance of 3 mm. Each set of SBPC had a corresponding measurer, and their length ranged from 20 to 35 mm. In 21 patients (67.7%) the SBPC were implanted in the posterior leaflet and in 10 patients (32.3%) in the anterior leaflet (in 2 patients concurrently in the anterior and posterior leaflets). All patients were assessed by ECO postoperatively, with a 20-month mean follow-up time (range 6-45 months).Results: One patient (3.2%) died of pulmonary embolism during the early postoperative period. Postoperative ECO showed absence of mitral regurgitation in 17 patients (54.8%), mild regurgitation in 9 (29.0%), and mild-to-moderate regurgitation in 4 (12.9%). Opening and mobility of the mitral valve were normal in the 30 surviving patients.Conclusion: The ECO revealed good functionality of the mitral valve apparatus with appropriate leaflet coaptation in patients who had undergone implantation of SBPC for replacement of ruptured or elongated and thinned chordae. A longer follow-up is required to assess absence of calcification and/or degeneration of the SBPC.

Differences in revascularization strategy and outcomes in ST-elevation and non-ST-elevation myocardial infarction with spontaneous coronary artery dissection

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
T Inohara ◽  
M Alfadhel ◽  
A Starovoytov ◽  
G.B John Mancini ◽  
J Saw
Keyword(s):  
Myocardial Infarction ◽  
Coronary Artery ◽  
Artery Dissection ◽  
Funding Source ◽  
Spontaneous Coronary Artery Dissection ◽  
Coronary Artery Dissection ◽  
Clinical Presentations ◽  
Increased Risk ◽  
St Elevation

Abstract Background Spontaneous coronary artery dissection (SCAD) is an important cause of myocardial infarction (MI) in young to middle-aged women. However, the role of revascularization for SCAD, especially percutaneous coronary intervention (PCI), remains controversial. Purpose To compare revascularization strategies and outcomes in SCAD patients presenting with ST-elevation MI (STEMI) vs. unstable angina or non-STEMI (UA/NSTEMI). Methods We analyzed SCAD patients who presented acutely between June 2014 and June 2018 to 22 centers participating in the Canadian SCAD Cohort Study. We compared treatment patterns and clinical outcomes in SCAD patients with an initial clinical presentation of STEMI vs. UA/NSTEMI. We assessed follow-up major adverse cardiovascular event (MACE) rate, a composite of all-cause death, MI, and stroke. The impact of revascularization on MACE was also evaluated according to clinical presentations (STEMI vs. UA/NSTEMI). Results Among 750 SCAD patients (mean age 51.7±10.5 years; 88.5% were women), 234 (31.2%) presented with STEMI. In the STEMI group, left anterior descending artery was more commonly involved (62.0% vs. 47.5%, p<0.001) and TIMI 0 flow was more frequently observed (24.8% vs. 7.2%, p<0.001). A total of 27.8% of STEMI patients were treated with revascularization (98.5% PCI), whereas only 8.7% of UA/NSTEMI patients were revascularized (93.3% PCI). For STEMI patients, 93.9% were planned procedures, whereas, for UA/NSTEMI patients, 71.1% were planned revascularization. Successful or partially successful PCI was 65.5% for STEMI and 76.9% for UA/NSTEMI (p<0.001). The median follow-up period was 850 (interquartile range: 619–1096) days. MACE rate was not different between STEMI and UA/NSTEMI (UA/NSTEMI as a reference: hazard ratio [HR] 1.08, 95% confidence interval [CI] 0.70–1.68, p=0.72). Regardless of clinical presentations, revascularization was associated with increased risk of MACE (STEMI: HR 2.57, CI 1.25–5.25, p=0.01; UA/NSTEMI: HR 5.41, CI 3.19–9.19, p<0.001). The association of revascularization and increased risk of MACE was more prominent in UA/NSTEMI than in STEMI (Figure), but it did not reach statistical significant (P for interaction = 0.09). Conclusions In SCAD patients, long-term clinical outcome was not different between STEMI and UA/NSTEMI presentations. Revascularization was more frequently performed with STEMI; however, regardless of clinical presentations, revascularization was associated with worse clinical outcomes. Careful patient selection for revascularization is key for SCAD patients and further studies are needed to clarify selection criteria. Revasc and MACE by presentation Funding Acknowledgement Type of funding source: Public grant(s) – National budget only. Main funding source(s): Canadian Institutes of Health Research

Extended Myectomy for Hypertrophic Obstructive Cardiomyopathy

2012 ◽  
Vol 15 (5) ◽  
pp. 251
Author(s):  
Changqing Gao ◽  
Chonglei Ren ◽  
Cangsong Xiao ◽  
Yang Wu ◽  
Gang Wang ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Left Ventricle ◽  
Mitral Regurgitation ◽  
Surgical Procedures ◽  
Hypertrophic Obstructive Cardiomyopathy ◽  
Systolic Anterior Motion ◽  
Anterior Leaflet ◽  
Septal Myectomy ◽  
The Mean

<p><b>Background:</b> The purpose of this study was to summarize our experience of extended ventricular septal myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM).</p><p><b>Methods:</b> Thirty-eight patients (26 men, 12 women) with HOCM underwent extended ventricular septal myectomy. The mean age was 36.3 years (range, 18-64 years). Diagnosis was made by echocardiography. The mean (mean � SE) systolic gradient between the left ventricle (LV) and the aorta was 89.3 � 31.1 mm Hg (range, 50-184 mm Hg) according to echocardiographic assessments before the operations. Moderate or severe systolic anterior motion (SAM) of the anterior leaflet of the mitral valve was found in 38 cases, and mitral regurgitation was present in 29 cases. Extended ventricular septal myectomy was performed in all 38 cases. The results of the surgical procedures were evaluated intraoperatively with transesophageal echocardiography (TEE) and with transthoracic echocardiography (TTE) at 1 to 2 weeks after the operation. All patients were followed up with TTE after their operation.</p><p><b>Results:</b> All patients were discharged without complications. The TEE evaluations showed that the mean systolic gradient between the LV and the aorta decreased from 94.8 � 35.6 mm Hg preoperatively to 13.6 � 10.8 mm Hg postoperatively (<i>P</i> = .0000) and that the mean thickness of the ventricular septum decreased from 28.3 � 7.9 mm to 11.8 � 3.2 mm (<i>P</i> = .0000). Mitral regurgitation and SAM were significantly reduced or eliminated. During the follow-up, all patients promptly became completely asymptomatic or complained of mild effort dyspnea only, and syncope was abolished. TTE examinations showed that the postoperative pressure gradient either remained the same or diminished.</p><p><b>Conclusions:</b> Extended ventricular septal myectomy is mostly an effective method for patients with HOCM, and good surgical exposure and thorough excision of the hypertrophic septum are of paramount importance for a successful surgery.</p>

The current treatment and predictors of outcome in elderly patients with non-ST-elevation myocardial infarction in an all comers population: the POPular Age registry

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M.E Gimbel ◽  
D.R.P.P Chan Pin Yin ◽  
R.S Hermanides ◽  
F Kauer ◽  
A.H Tavenier ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Elderly Patients ◽  
Major Bleeding ◽  
Oral Anticoagulation ◽  
Dual Antiplatelet Therapy ◽  
Bleeding Risk ◽  
Cardiovascular Death ◽  
St Elevation ◽  
One Year

Abstract Background Elderly patients form a large and growing part of the patients presenting with non-ST-elevation myocardial infarction (NSTEMI). Choosing the optimal antithrombotic treatment in these elderly patients is more complicated because they frequently have characteristics indicating both a high ischaemic and high bleeding risk. Purpose We describe the treatment of elderly patients (&gt;75 years) admitted with NSTEMI, present the outcomes (major adverse cardiovascular events (MACE) and bleeding) and aim to find predictors for adverse events. Methods The POPular AGE registry is an investigator initiated, prospective, observational, multicentre study of patients aged 75 years or older presenting with NSTEMI. Patients were recruited between August 1st, 2016 and May 7th, 2018 at 21 sites in the Netherlands. The primary composite endpoint of MACE included cardiovascular death, non-fatal myocardial infarction and non-fatal stroke at one-year follow-up. Results A total of 757 patients were enrolled. During hospital stay 76% underwent coronary angiography, 34% percutaneous coronary intervention and 12% coronary artery bypass grafting (CABG). At discharge 78.6% received aspirin (non-users mostly because of the combination of oral anticoagulant and clopidogrel), 49.7% were treated with clopidogrel, 34.2% with ticagrelor and 29.6% were prescribed oral anticoagulation. Eighty-three percent of patients received dual antiplatelet therapy (DAPT) or dual therapy consisting of oral anticoagulation and at least one antiplatelet agent for a duration of 12 months. At one year, the primary outcome of cardiovascular death, myocardial infarction or stroke occurred in 12.3% of patients and major bleeding (BARC 3 or 5) occurred in 4.8% of the patients. The risk of MACE and major bleeding was highest during the first month and stayed high over time for MACE while the risk for major bleeding levelled off. Independent predictors for MACE were age, renal function, medical history of CABG, stroke and diabetes. The only independent predictor for major bleeding was haemoglobin level on admission. Conclusion In this all-comers registry, most elderly patients (≥75 years) with NSTEMI are treated with DAPT and undergoing coronary angiography the same way as younger NSTEMI patients from the SWEDEHEART registry. Aspirin use was lower as was the use of the more potent P2Y12 inhibitors compared to the SWEDEHEART which is very likely due to the concomitant use of oral anticoagulation in 30% of patients. The fact that ischemic risk stays constant over 1 year of follow-up, while the bleeding risk levels off after one month may suggest the need of dual antiplatelet therapy until at least one year after NSTEMI. Funding Acknowledgement Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): AstraZeneca

The effect of preloading statins prior to primary reperfusion on in-hospital mortality risk in a contemporary large-scale cohort of patients with ST-elevation myocardial infarction

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
R Fu ◽  
C.X Song ◽  
X.D Li ◽  
Y.J Yang
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Hospital Mortality ◽  
Mortality Risk ◽  
Large Scale ◽  
Reperfusion Therapy ◽  
St Elevation Myocardial Infarction ◽  
Control Group ◽  
Funding Source ◽  
St Elevation

Abstract Background The benefit of statins in secondary prevention of patients stabilized after acute coronary syndrome (ACS) has been well established. However, the benefit of preloading statins, i.e. high-intensity statins prior to reperfusion therapy remains unclear. Most previous studies included all types of ACS patients, and subgroup analysis indicated the benefit of preloading statins was only seen in ST-elevation myocardial infarction (STEMI) patients who underwent percutaneous coronary intervention (PCI). However, the sample size of subgroup population was relatively small and such benefit requires further validation. Objective To investigate the effect of loading dose of statins before primary reperfusion on 30-mortality in patients with STEMI. Methods We enrolled patients in China Acute Myocardial Infarction (CAMI) registry from January 2013 to September 2014. CAMI registry was a prospective multicenter registry of patients with acute acute myocardial infarction in China. Patients were divided into two groups according to statins usage: preloading group and control group. Patients in preloading group received loading does of statins before primary reperfusion and during hospitalization. Patients in control group did not receive statins during hospitalization or at discharge. Primary outcome was in-hospital mortality. Baseline characteristics, angiographic characteristics and outcome were compared between groups. Propensity score (PS) matching was used to mitigate baseline differences between groups and examine the association between preloading statins on in-hospital mortality risk. The following variables were used to establish PS matching score: age, sex, classification of hospitals, clinical presentation (heart failure at presentation, cardiac shock, cardiac arrest, Killip classification), hypertension, diabetes, prior angina, prior myocardial infarction history, prior stroke, initial treatment. Results A total of 1169 patients were enrolled in control group and 6795 in preloading group. A total of 833 patients (334 in control group and 499 in preloading group) died during hospitalization. Compared with control group, preloading group were younger, more likely to be male and present with Killip I classification. The proportion of hypertension and diabetes were higher in preloading group. After PS matching, all the variables used to generate PS score were well balanced. In the PS-matched cohort, 30-day mortality risk was 26.3% (292/1112) in the control group and 11.9% (132/1112) in the preloading group (p&lt;0.0001). Conclusions The current study found preloading statins treatment prior to reperfusion therapy reduced in-hospital mortality risk in a large-scale contemporary cohort of patients with STEMI. Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Chinese Academy of Medical Sciences

Sign in / Sign up

Export Citation Format

Share Document